Comments
Loading...

Biomarin Pharmaceutical

BMRNNASDAQ
$85.89
00.00%
Last update: 4:00 PM
15 minutes delayed
Consensus Rating1
Overweight
Highest Price Target1
$185.00
Lowest Price Target1
$70.00
Consensus Price Target1
$107.16

want to know what
the Bulls & Bears Say?

Biomarin Pharmaceutical (NASDAQ:BMRN) Stock, Analyst Ratings, Price Targets, Forecasts

Biomarin Pharmaceutical Inc has a consensus price target of $107.16 based on the ratings of 28 analysts. The high is $185 issued by B of A Securities on July 21, 2023. The low is $70 issued by Wedbush on August 1, 2023. The 3 most-recent analyst ratings were released by Wells Fargo, Baird, and Evercore ISI Group on June 27, 2024, May 17, 2024, and May 14, 2024, respectively. With an average price target of $100 between Wells Fargo, Baird, and Evercore ISI Group, there's an implied 16.43% upside for Biomarin Pharmaceutical Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jan
2
Feb
3
1
Apr
1
1
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wells Fargo
Baird
Evercore ISI Group
Morgan Stanley
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for Biomarin Pharmaceutical

Buy NowGet Alert
06/27/2024Buy Now33.89%Wells Fargo
Mohit Bansal
$110 → $115MaintainsOverweightGet Alert
05/17/2024Buy Now-16.17%Baird
Joel Beatty
$104 → $72DowngradeOutperform → NeutralGet Alert
05/14/2024Buy Now31.56%Evercore ISI Group
Cory Kasimov
→ $113Initiates → OutperformGet Alert
04/26/2024Buy Now30.4%Morgan Stanley
Matthew Harrison
$115 → $112MaintainsOverweightGet Alert
04/26/2024Buy Now3.62%Canaccord Genuity
Whitney Ijem
$91 → $89MaintainsHoldGet Alert
04/25/2024Buy Now28.07%Cantor Fitzgerald
Olivia Brayer
→ $110ReiteratesOverweight → OverweightGet Alert
04/25/2024Buy Now5.95%Citigroup
David Lebovitz
$94 → $91MaintainsNeutralGet Alert
04/25/2024Buy Now-1.04%Scotiabank
George Farmer
$83 → $85MaintainsSector PerformGet Alert
04/25/2024Buy Now28.07%Wells Fargo
Mohit Bansal
$100 → $110MaintainsOverweightGet Alert
02/29/2024Buy Now5.95%Canaccord Genuity
Whitney Ijem
→ $91ReiteratesHold → HoldGet Alert
02/23/2024Buy Now24.58%Piper Sandler
Christopher Raymond
$115 → $107MaintainsOverweightGet Alert
02/23/2024Buy Now16.43%Cantor Fitzgerald
Olivia Brayer
→ $100ReiteratesOverweight → OverweightGet Alert
02/23/2024Buy Now16.43%RBC Capital
Luca Issi
→ $100ReiteratesSector Perform → Sector PerformGet Alert
01/30/2024Buy Now21.09%Baird
Joel Beatty
$127 → $104MaintainsOutperformGet Alert
12/21/2023Buy Now17.59%Stifel
Paul Matteis
→ $101ReiteratesBuy → BuyGet Alert
11/07/2023Buy Now16.43%RBC Capital
Luca Issi
$100 → $100ReiteratesSector Perform → Sector PerformGet Alert
11/03/2023Buy Now16.43%BMO Capital
Kostas Biliouris
$102 → $100MaintainsOutperformGet Alert
11/02/2023Buy Now33.89%Piper Sandler
Christopher Raymond
$125 → $115MaintainsOverweightGet Alert
11/02/2023Buy Now36.22%Morgan Stanley
Matthew Harrison
$125 → $117MaintainsOverweightGet Alert
11/02/2023Buy Now29.24%Barclays
Gena Wang
$125 → $111MaintainsOverweightGet Alert
11/02/2023Buy Now16.43%Cantor Fitzgerald
Olivia Brayer
$120 → $100MaintainsOverweightGet Alert
10/23/2023Buy Now-4.53%Bernstein
William Pickering
→ $82UpgradeUnderperform → Market PerformGet Alert
10/16/2023Buy Now39.71%Cantor Fitzgerald
Olivia Brayer
→ $120ReiteratesOverweight → OverweightGet Alert
09/28/2023Buy NowRaymond James
Laura Chico
Initiates → Market PerformGet Alert
09/25/2023Buy Now63%Truist Securities
Robyn Karnauskas
→ $140ReiteratesBuy → BuyGet Alert
09/18/2023Buy Now39.71%UBS
Martin Auster
→ $120Initiates → BuyGet Alert
09/15/2023Buy Now63%Truist Securities
Robyn Karnauskas
→ $140ReiteratesBuy → BuyGet Alert
09/14/2023Buy Now39.71%Cantor Fitzgerald
Olivia Brayer
→ $120ReiteratesOverweight → OverweightGet Alert
09/13/2023Buy Now28.07%Guggenheim
Debjit Chattopadhyay
→ $110ReiteratesBuy → BuyGet Alert
09/13/2023Buy Now16.43%RBC Capital
Luca Issi
→ $100ReiteratesSector Perform → Sector PerformGet Alert
09/13/2023Buy Now39.71%Cantor Fitzgerald
Olivia Brayer
→ $120ReiteratesOverweight → OverweightGet Alert
08/01/2023Buy Now45.53%Morgan Stanley
Matthew Harrison
$129 → $125MaintainsOverweightGet Alert
08/01/2023Buy Now25.74%Stifel
Paul Matteis
$118 → $108MaintainsBuyGet Alert
08/01/2023Buy Now-18.5%Wedbush
Andreas Argyrides
$73 → $70MaintainsNeutralGet Alert
08/01/2023Buy Now39.71%Cantor Fitzgerald
Olivia Brayer
→ $120ReiteratesOverweight → OverweightGet Alert
08/01/2023Buy Now16.43%RBC Capital
Luca Issi
→ $100ReiteratesSector Perform → Sector PerformGet Alert
07/27/2023Buy Now10.61%Scotiabank
George Farmer
→ $95Initiates → Sector PerformGet Alert
07/21/2023Buy Now115.39%B of A Securities
Geoff Meacham
$200 → $185MaintainsBuyGet Alert
07/05/2023Buy Now18.76%BMO Capital
Kostas Biliouris
→ $102UpgradeMarket Perform → OutperformGet Alert
07/03/2023Buy Now21.09%Canaccord Genuity
Whitney Ijem
$110 → $104MaintainsHoldGet Alert
06/30/2023Buy Now11.77%Citigroup
David Lebowitz
$103 → $96MaintainsNeutralGet Alert
06/30/2023Buy Now47.86%Baird
Joel Beatty
→ $127ReiteratesOutperform → OutperformGet Alert
06/30/2023Buy Now-15.01%Wedbush
Andreas Argyrides
$69 → $73MaintainsNeutralGet Alert
06/30/2023Buy Now63%Truist Securities
Robyn Karnauskas
$125 → $140MaintainsBuyGet Alert
06/14/2023Buy Now39.71%Credit Suisse
Tiago Fauth
→ $120Assumes → OutperformGet Alert
04/27/2023Buy Now19.92%Citigroup
David Lebowitz
$114 → $103MaintainsNeutralGet Alert
04/27/2023Buy Now39.71%Guggenheim
Debjit Chattopadhyay
$125 → $120MaintainsBuyGet Alert
04/27/2023Buy Now45.53%Piper Sandler
Christopher Raymond
$128 → $125MaintainsOverweightGet Alert
04/27/2023Buy Now16.43%RBC Capital
Luca Issi
→ $100Reiterates → Sector PerformGet Alert
04/27/2023Buy Now-19.66%Wedbush
Andreas Argyrides
$74 → $69MaintainsNeutralGet Alert
04/27/2023Buy Now39.71%Credit Suisse
Tiago Fauth
$122 → $120MaintainsOutperformGet Alert
04/27/2023Buy Now47.86%Baird
Joel Beatty
$112 → $127MaintainsOutperformGet Alert
03/21/2023Buy Now-5.69%Bernstein
William Pickering
→ $81Initiates → UnderperformGet Alert
03/07/2023Buy Now18.76%BMO Capital
Kostas Biliouris
$107 → $102MaintainsMarket PerformGet Alert
02/28/2023Buy Now45.53%Guggenheim
Debjit Chattopadhyay
→ $125Reiterates → BuyGet Alert
02/28/2023Buy Now37.39%Stifel
Paul Matteis
$114 → $118MaintainsBuyGet Alert
02/28/2023Buy Now-13.84%Wedbush
Andreas Argyrides
$83 → $74MaintainsNeutralGet Alert
02/28/2023Buy Now30.4%Canaccord Genuity
Whitney Ijem
$119 → $112MaintainsHoldGet Alert
02/28/2023Buy Now52.52%Morgan Stanley
Matthew Harrison
$132 → $131MaintainsOverweightGet Alert
02/28/2023Buy Now47.86%Credit Suisse
Tiago Fauth
$110 → $127MaintainsOutperformGet Alert
02/22/2023Buy NowOppenheimer
Leland Gershell
DowngradeOutperform → PerformGet Alert
02/21/2023Buy Now35.06%Citigroup
David Lebowitz
→ $116Initiates → NeutralGet Alert
02/03/2023Buy Now51.36%SVB Leerink
Joseph Schwartz
$122 → $130MaintainsOutperformGet Alert
01/30/2023Buy Now24.58%BMO Capital
Kostas Biliouris
→ $107Initiates → Market PerformGet Alert
01/24/2023Buy Now53.68%Morgan Stanley
Matthew Harrison
$113 → $132MaintainsOverweightGet Alert
01/18/2023Buy Now38.55%Canaccord Genuity
Whitney Ijem
→ $119Initiates → HoldGet Alert
01/11/2023Buy Now-3.36%Wedbush
Andreas Argyrides
$74 → $83MaintainsNeutralGet Alert
11/29/2022Buy Now39.71%Jefferies
Akash Tewari
$100 → $120MaintainsBuyGet Alert
10/31/2022Buy Now28.07%Oppenheimer
Leland Gershell
$92 → $110UpgradePerform → OutperformGet Alert
10/27/2022Buy Now28.07%Credit Suisse
Tiago Fauth
$111 → $110MaintainsOutperformGet Alert
10/27/2022Buy Now31.56%Morgan Stanley
Matthew Harrison
$111 → $113MaintainsOverweightGet Alert
10/24/2022Buy Now30.4%JP Morgan
Jessica Fye
$140 → $112MaintainsOverweightGet Alert
10/13/2022Buy Now10.61%RBC Capital
Luca Issi
$90 → $95MaintainsSector PerformGet Alert
10/13/2022Buy Now29.24%Morgan Stanley
Matthew Harrison
$117 → $111MaintainsOverweightGet Alert
08/09/2022Buy Now49.03%Piper Sandler
Christopher Raymond
$125 → $128MaintainsOverweightGet Alert
08/04/2022Buy Now36.22%Morgan Stanley
Matthew Harrison
$113 → $117MaintainsOverweightGet Alert
08/04/2022Buy Now42.04%SVB Leerink
Joseph Schwartz
$115 → $122MaintainsOutperformGet Alert
08/04/2022Buy Now45.53%Barclays
Gena Wang
$112 → $125MaintainsOverweightGet Alert
07/13/2022Buy Now28.07%Cantor Fitzgerald
Olivia Brayer
→ $110Initiates → OverweightGet Alert
06/13/2022Buy Now-18.5%Wedbush
Andreas Argyrides
→ $70Assumes → NeutralGet Alert
06/06/2022Buy Now23.41%Credit Suisse
Tiago Fauth
$105 → $106MaintainsOutperformGet Alert
04/25/2022Buy Now31.56%Morgan Stanley
Matthew Harrison
$96 → $113UpgradeEqual-Weight → OverweightGet Alert
04/12/2022Buy Now11.77%Morgan Stanley
Matthew Harrison
$90 → $96MaintainsEqual-WeightGet Alert
02/24/2022Buy Now45.53%Piper Sandler
Christopher Raymond
$121 → $125MaintainsOverweightGet Alert
11/22/2021Buy Now22.25%Credit Suisse
Tiago Fauth
MaintainsOutperformGet Alert
11/22/2021Buy Now4.79%Morgan Stanley
Matthew Harrison
MaintainsEqual-WeightGet Alert
11/22/2021Buy NowWilliam Blair
Tim Lugo
UpgradeMarket Perform → OutperformGet Alert
11/22/2021Buy Now33.89%SVB Leerink
Joseph Schwartz
MaintainsOutperformGet Alert
11/15/2021Buy Now30.4%SVB Leerink
Joseph Schwartz
MaintainsOutperformGet Alert
10/28/2021Buy Now16.43%Credit Suisse
Tiago Fauth
MaintainsOutperformGet Alert
09/09/2021Buy Now11.77%Stifel
Paul Matteis
UpgradeHold → BuyGet Alert
07/29/2021Buy Now2.46%RBC Capital
Kennen MacKay
MaintainsSector PerformGet Alert

FAQ

Q

What is the target price for Biomarin Pharmaceutical (BMRN) stock?

A

The latest price target for Biomarin Pharmaceutical (NASDAQ:BMRN) was reported by Wells Fargo on June 27, 2024. The analyst firm set a price target for $115.00 expecting BMRN to rise to within 12 months (a possible 33.89% upside). 38 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Biomarin Pharmaceutical (BMRN)?

A

The latest analyst rating for Biomarin Pharmaceutical (NASDAQ:BMRN) was provided by Wells Fargo, and Biomarin Pharmaceutical maintained their overweight rating.

Q

When was the last upgrade for Biomarin Pharmaceutical (BMRN)?

A

The last upgrade for Biomarin Pharmaceutical Inc happened on October 23, 2023 when Bernstein raised their price target to $82. Bernstein previously had an underperform for Biomarin Pharmaceutical Inc.

Q

When was the last downgrade for Biomarin Pharmaceutical (BMRN)?

A

The last downgrade for Biomarin Pharmaceutical Inc happened on May 17, 2024 when Baird changed their price target from $104 to $72 for Biomarin Pharmaceutical Inc.

Q

When is the next analyst rating going to be posted or updated for Biomarin Pharmaceutical (BMRN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biomarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biomarin Pharmaceutical was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.

Q

Is the Analyst Rating Biomarin Pharmaceutical (BMRN) correct?

A

While ratings are subjective and will change, the latest Biomarin Pharmaceutical (BMRN) rating was a maintained with a price target of $110.00 to $115.00. The current price Biomarin Pharmaceutical (BMRN) is trading at is $85.89, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch